Quick comparison
| Mounjaro | Wegovy | |
|---|---|---|
| Active ingredient | tirzepatide | semaglutide |
| Mechanism | GIP / GLP-1 | GLP-1 |
| Administration | once-weekly injection | once-weekly injection or daily tablet |
| EU weight management | authorised for defined patient groups | authorised for defined patient groups |
What drives the choice
A clinician considers medical history, current medicines, contraindications, previous treatment, tolerance, treatment goals and availability. A group average from a clinical trial is not enough to choose a medicine for one person.
Effectiveness evidence
Direct clinical trials comparing tirzepatide and semaglutide in obesity are available. Group-level results cannot guarantee an individual outcome and should be interpreted alongside safety and medical context.
SURMOUNT-5 · NEJM 202572 weeks · n=751 · tirzepatide −20.2% · semaglutide −13.7%.NEJM ↗
Price and availability
Prices are not harmonised across the EU and may vary by country, pack, dose, supply and reimbursement rules.
Related topics
Mounjaro and weight management: what to know about tirzepatideMounjaro contains tirzepatide. In the EU it has an authorised indication for weight management in defined groups of adults, in addition to its type 2 diabetes indication.→
Wegovy and weight management: what to know about semaglutideWegovy contains semaglutide and is authorised in the EU for weight management in defined patient groups. Since 2026, EU product information includes both weekly injections and daily oral tablets for adults.→
Mounjaro price: why there is no single price across EuropeSearch results for “Mounjaro price” often show numbers that apply to one country, one pack or an old date. The useful figure is the current local price and reimbursement status where you live.→
Sources and review
Information is based on European regulatory sources. Availability, reimbursement and prescribing rules vary between EU countries.
Sources last checked: 1 September 2026.